Key Highlights

  • AML3D shares rose 12.20% to AUD 0.115 on Volume of approximately 5.06mn shares.
  • The FY26 order book peaked at a record AUD 29mn, with AUD 16.8mn rolling into FY27.
  • FY26 cash receipts reached approximately AUD 10.4mn, including AUD 3.5mn in the June quarter.
  • The company commissioned its first ARCEMY systems at Newport News Shipbuilding in the United States.

AML3D Limited (ASX:AL3) advanced 12.20% to AUD 0.115 as the market revisited a defence-led order book that reached a record level in FY26. The company secured around AUD 20mn of new orders during the year and carried AUD 16.8mn into FY27, improving near-term Revenue visibility. Its first systems at Newport News Shipbuilding also moved from order to commissioning. The remaining challenge is converting Backlog into installations, customer acceptance and cash while expanding across the United States and Europe.

Company Overview

AML3D designs and manufactures ARCEMY industrial metal-printing systems using proprietary wire-additive Manufacturing technology. The equipment produces large metal components for defence, maritime, aerospace, energy and industrial customers. The strategy increasingly centres on supplying allied defence manufacturing networks, where local production and qualified parts may reduce supply-chain dependence.

Record Backlog Moves Into Delivery

AML3D’s June-quarter update reported a peak FY26 order book of AUD 29mn, supported by approximately AUD 20mn of new orders during the year. About AUD 16.8mn was scheduled to roll into FY27. The company also commissioned its first approximately AUD 4.1mn ARCEMY systems at Newport News Shipbuilding, a major US military shipbuilder. These milestones provide delivery visibility, although revenue recognition and cash timing depend on manufacturing, installation and acceptance.

Financial and Share Price Snapshot

AL3 closed at AUD 0.115 after gaining 12.20%, with volume of approximately 5.06mn shares. The supplied Market Capitalisation was AUD 65.26mn and the one-year return was negative 56.60%. FY26 cash receipts reached around AUD 10.4mn, including AUD 3.5mn in the June quarter. The share-price rebound must therefore be assessed against backlog conversion, operating expenditure and the capital required to support international growth.

What Investors May Watch Next

Investors may track delivery of the FY27 opening order book, further US defence orders and utilisation of the Ohio Facility . System reliability, customer acceptance, gross margins and service revenue will indicate whether ARCEMY can scale beyond individual projects. Cash receipts, inventory, staffing and European distribution are also relevant to the funding outlook.

Risks

  • Large system deliveries may be delayed or Fail customer acceptance.
  • Defence procurement cycles can be lengthy and concentrated.
  • International expansion may raise costs before revenue is recognised.
  • Technology performance and intellectual-property protection remain important.
  • Further funding could dilute shareholders if cash conversion lags.